TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change of hepatic iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Retinal blood flow velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical success of the STABILISE procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of paralysis at D2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRD by FCM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Donor chimerism (DC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dapivirine concentration in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Levonorgestrel concentration in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dapivirine concentration in vaginal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levonorgestrel concentration in vaginal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Imiquimod treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants who die within 90 days after surgery
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants who undergo revision surgery of the treated hip
Endpoint domain: Adverse events/effects
Primary endpoint: Zinc balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Alleviation of Clinical Signs and Symptoms of Influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of change on the 17-item Hamilton Rating Scale for Depression (HAM-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Trunk extensor fMRI signal intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental health of parents
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Direct Classroom Observations of Student Behavior
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Teacher Ratings of Student On-task and Aggressive-disruptive Behavior
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cumulative Combined Unique Active Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in QUEST Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Shoulder Range of Motion Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: VAS (Visual Analog Scale) Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASES Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 5-year Relapse-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Safety of ipilimumab and dabrafenib in combination
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity to heat and cold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity to mechanical stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute intracranial pressure (aICP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Car Seat Installation Demonstration Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of illicit ATS use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EEG power spectra
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Resolution of influenza symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of non-response to empiric antimicrobial treatment
Endpoint domain: Adverse events/effects
Primary endpoint: WHO_BREF questioner (Quality of life)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quantitative Stimulus Testing (QST)-Thermal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Liver biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blood work
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse experience
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Medically Attended Adverse Events (MAEs) and Serious Adverse Events (SAEs) Through 12 Months After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: occurrence of peri-implantitis
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Psychotic Symptom Rating Scale - Auditory Hallucinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Repairment of the cervico-vaginal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brain electrical responses amplitudes and latencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Alpha 1-antitrypsin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of fexinidazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and feasibility
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Stimulated C-peptide Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of hospitalisations due to COPD exacerbations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in angle of deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modification of Cormack and Lehane grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: pain intensity of headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of target area non-vellus hair count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of maintaining optimal ART
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days to Full Enteral Feeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Comfort and safety when operating adult ATV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change scores on pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change scores on fatigue scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change scores on nausea scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change scores on anxiety scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Toxicity Evaluation
Endpoint domain: Adverse events/effects
Primary endpoint: Intimal Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of veliparib
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of difficult mask ventilation and intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pain following burn injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total surgical complications
Endpoint domain: Adverse events/effects
Primary endpoint: Superficial incisional surgical site infection (SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Deep/organ SSI
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity for CRC of the FirstSight test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the FirstSight test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: iAUC glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resolution of VMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full thickness macular hole (FTMH) closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evoked potentials related to prediction mechanisms during visual processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral responses related to prediction mechanisms during visual processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with injury-induced-immunosuppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of night awakenings due to asthma symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of days with asthma-related activity limitations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Annual Rate of Decline in Forced Vital Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Estimated Percentage of Participants in Blood Pressure Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood Pressure Averages Systolic & Diastolic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of INK4a-p16 germline mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Biologic activity of identified INK4a-p16 germline mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Perceived Hearing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of lung cancers diagnosed by sputum cytology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy of MCG to detect myocardial ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ultrasound findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile of ATV-SQV-RTV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile of SQV/r
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durability and safety of the regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Decay pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Claudication Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total vitamin A liver reserves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pathologic complete response rate (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major pathological response (MPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unacceptable toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Where the Device Accessed, Deployed and Was Positioned in the Aortic Arch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Serious Adverse Events Related to Investigational Device and Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative atrial fibrillation (POAF) incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression Free Survival (PFS) Rate at 16 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: Progression Free Survival (PFS) Rate at 11 Months
Endpoint domain: Mortality/survival
Primary endpoint: Detection of biofilm-associated pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Negative Reaction at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Negative Reaction at 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Verbal Rating Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Objective Response Rate (RECIST v 1.1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mechanical failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Final outcomes of patients with tuberculosis infection
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of liver cancer
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of decompensated cirrhosis
Endpoint domain: Mortality/survival
Primary endpoint: Level of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: postprandial insulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of weaning failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of AMG 386
Endpoint domain: Adverse events/effects
Primary endpoint: PTSD questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of glucose sensor readings within target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in bipolar manic or mixed symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving a total daily prednisone dose of </=10 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ImageJ scoring system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of asthma exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HFNC failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of chromosomal abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of structural defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of genetic syndromes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Resumption of normal cavity on hystero-salpingography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete or Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Disappearance of All Target Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 30% Decrease in the Sum of the Longest Diameter of Target Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Phthalates exposure levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visualization rate of IMSLN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of TKI258
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Complications of Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Safety grade by CTCAE version 4.0
Endpoint domain: Adverse events/effects
Primary endpoint: Marijuana Craving Questionnaire (MCQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pressure/volume measurements of vagina
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with undetectable plasma HIV-1 RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-suicidal self-harm
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of sCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of negative MRD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specimen Acceptance Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 30-day mortality and morbidity
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Treatment Responses
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical laboratory tests for safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rehabilitation time for 90° flexion of the knee joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Light scattering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunohistochemistry (IHC) expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean peak plasma concentration (Cmax) of MTP-131 (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abandonment rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in gastric emptying half-time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Creatinine clearance estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Neuron specific enolase (NSE) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of patients requiring rescue analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline of posture and movement patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Effectiveness of treatment duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Laryngeal function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esophagitis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 30 day readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area under the plasma concentration-time curve from zero to infinity for osimertinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration for osimertinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of key care processes in diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD8+ T cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in 24-hour ambulatory mean systolic daytime blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anxiety 4a T Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Urinary Distress Inventory (UDI-6)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Progression of Renal Graft Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent change of HOMA insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent change of TG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Schiff Cold Air Sensitivity Scale Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale (VAS) Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dentin Hypersensitivity Experience Questionnaire (DHEQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glycosylated albumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Activity of daily life function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Difference in cell volume of cancer or diagnostic tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: physical exam profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bleeding time measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in Oxygen Saturation (SpO2) Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Treatment-Related Adverse Events as Assessed by CTCAE v4.0
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Return to Previous Levels of Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Antibody Geometric Mean Concentrations (GMCs) Against Pneumococcal Serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Descriptive activity of brain with dMRI results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Descriptive functional responses elicited by the direct electrostimulation of the cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hunger Satiety Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cardiovascular Fitness (Lokomat Peak VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes